What guidance did Abbvie's management provide for the next earnings period?

What were the key takeaways from Abbvie's earnings call?

Did Abbvie beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Abbvie next quarter?

What is Abbvie's gross profit margin?

What factors drove the changes in Abbvie's revenue and profit?

What were the key takeaways from Abbvie’s earnings call?

What is the revenue and EPS growth rate for Abbvie year over year?

- **Record Growth**: Q3 revenue $15.8B (+8.4% YoY), beating estimates by $300M.
- **Pipeline Power**: Skyrizi/Rinvoq at $17.3B+ in 2025, neuroscience up 19.6% to $2.8B.
- **Dividend Boost**: 5.5% increase to $1.73/share, supported by $13B+ free cash flow.
- **Strategic Expansion**: $10B+ U.S. manufacturing investment; new API plant and biologics expansion.
- **Resilience**: Outperformed in oncology (+$1.7B), neuroscience (+$2.8B), despite macro headwinds in aesthetics.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $15.8 billion (+8.4% YoY), driven by 46% growth in Skyrizi and 34% in Rinvoq.
- **Pipeline Momentum**: 90+ programs across immunology, oncology, neuroscience, and aesthetics; Phase III data for Rinvoq in vitiligo and alopecia areata expected soon.
- **Strategic Investments**: $10 billion+ in U.S. manufacturing; new API plant in North Chicago and biologics expansion in Worcester.
- **Dividend Increase**: 5.5% hike to $1.73/share, reflecting strong free cash flow ($13B+ YTD).

**【CFO Financial Commentary】**
- **Earnings**: Adjusted EPS of $1.86 (vs. $1.76 guidance), with $400M revenue beat.
- **Margins**: Gross margin 83.9%, R&D 14.3%, SG&A 21.6%; operating margin 30.9%.
- **2025 Guidance Update**: Full-year revenue $16.9B (+$400M), EPS $10.61-$10.65.
- **2026 Outlook**: Expects high single-digit growth, supported by Skyrizi/Rinvoq (~$17.3B) and neuroscience (~$10.7B).

**【Q&A Highlights】**
- **PBM Model**: CEO confident in AbbVie's ability to adapt; differentiated medicines (e.g., VYALEV, tavapadon) mitigate PBM risks.
- **Aesthetics Recovery**: BOTOX share ~60%, Juvederm ~45%; new campaigns and TrenibotE launch in 2026 may drive rebound.
- **Pipeline Catalysts**: Rinvoq vitiligo/vitiligo data (Q4 2025), tavapadon FDA submission (Q4 2025), Temab-A Phase III in CRC (2026).

ABBV

ABBV fundamentals

You can ask Aime